FRESENIUS KABI ONCOLOGY LTD.

NSE : NABSE : 532545ISIN CODE : INE575G01010Industry : Pharmaceuticals & DrugsHouse : Fresenius Kabi Oncology - MNC
BSE132.450 (0 %)
PREV CLOSE ( ) 132.45
OPEN PRICE ( ) 132.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 132.45 (20430)
VOLUME 91518
TODAY'S LOW / HIGH ( )132.00 132.60
52 WK LOW / HIGH ( ) 132132.6
NSE
This Company is not listed in NSE
( in Million)
Select year
ParticularsMar2011Mar2010Mar2009Mar2008Mar2007
Profit Before Tax367.65-296.48-1432.34-197.95244.00
Adjustment623.13743.81470.04215.6098.61
Changes In working Capital-488.03-721.34-892.95-243.82-211.17
Cash Flow after changes in Working Capital502.74-274.02-1855.25-226.16131.45
Cash Flow from Operating Activities27.02-723.74-1866.45-275.1186.77
Cash Flow from Investing Activities-1223.63-660.73534.9779.99-1323.57
Cash Flow from Financing Activities1023.381504.441408.63328.62742.49
Net Cash Inflow / Outflow-173.23119.9777.16133.50-494.31
Opening Cash & Cash Equivalents407.35287.37210.2276.72571.03
Cash & Cash Equivalent on Amalgamation / Take over / MergerNANANANANA
Cash & Cash Equivalent of Subsidiaries under liquidationsNANANANANA
Translation adjustment on reserves / op cash balalces frgn subsidiariesNANANANANA
Effect of Foreign Exchange FluctuationsNANANANANA
Closing Cash & Cash Equivalent234.12407.35287.37210.2276.72

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.